Back to search
Osteoporosis, Post-menopausal
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Osteoporosis, Post-menopausal trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Osteoporosis, Post-menopausal trials you may qualify forIn this research study the study investigators want to learn more about the effect of two different FDA-approved medication regimens in the treatment of postmen…
During menopause, estrogen levels drop while the level of another hormone - LH (luteinizing hormone) substantially increases. This hormonal shift is linked to b…
Osteoporosis is a progressive disease characterised by a decrease in bone mass, deterioration in bone microarchitecture, and increased fragility. Etiologically,…
Dietary interventions of prune consumption during the transmenopausal period are innovative methods to prevent bone loss. Modern medicine does not intervene to…
Denosumab (Dmab) is a treatment for postmenopausal osteoporosis. However, its withdrawal is associated with a rebound phenomenon associated with an unexpected i…
This study is a prospective, randomized, controlled clinical trial comparing the efficacy of a 24-month cyclic therapy regimen (6 months of Romosozumab followed…
Evaluate whether treatment with a widely used beta blocker, atenolol, will prevent bone loss at the lower back and hip in postmenopausal women.
In this research study we want to learn more about the effect of two different FDA-approved medications in the treatment of osteoporosis.
It is estimated that women lose around 20-25% of bone mass during the 5-10 years period of postmenopausal transition, and menopause is considered a major risk f…